Sugi Predict

Sugi Predict / Compounds / SCHEMBL443240

SCHEMBL443240

SCHEMBL443240

CC(C)(C)OC(=O)N1Cc2nc(Cl)nc(Cl)c2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.40
▸ PARP1 P09874 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ C5AR1 P21730 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ DDB1 Q16531 2/20 0.35
▸ CRBN Q96SW2 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NR1H2 P55055 1/20 0.34
▸ STS P08842 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417213 0.88 ESR2 (0.45) POLBPARP1TNKS2PARP2MTOR
SCHEMBL1832511 0.88 PARP1 (0.47) POLBPARP1TNKS2PARP2MTOR
SCHEMBL30887681 0.88 ESR2 (0.45) POLBPARP1TNKS2PARP2MTOR
SCHEMBL28672930 0.87 POLB (0.39) POLBPARP1TNKS2PARP2MTOR
SCHEMBL22165616 0.87 C5AR1 (0.39) POLBPARP1TNKS2PARP2MTOR
SCHEMBL30995392 0.86 PARP1 (0.39) POLBPARP1TNKS2PARP2MTOR
SCHEMBL22165322 0.85 C5AR1 (0.39) POLBPARP1TNKS2PARP2MTOR
SCHEMBL2810029 0.84 MEN1 (0.36) POLBPARP1TNKS2PARP2MTOR
SCHEMBL31016583 0.84 MKNK1 (0.38) POLBPARP1TNKS2PARP2MTOR
SCHEMBL27393879 0.83 MKNK1 (0.37) POLBPARP1TNKS2PARP2MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146050-A1 KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-05-28 — — US disclosed
WO-2026107349-A1 HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES ANTARES THERAPEUTICS, INC. (US) 2026-05-21 — — WO disclosed
US-12630552-B2 Inhibitors of KRAS G12C BEONE MEDICINES I GMBH (CH) 2026-05-19 — — US disclosed
WO-2026099455-A1 DIHYDROPYRROLOPYRIMIDINONE COMPOUNDS AS TREM2 MODULATORS MUNA THERAPEUTICS APS (DK) 2026-05-15 — — WO disclosed
EP-4737453-A1 NOVEL SELENOPHENE DERIVATIVES Aigen Sciences Inc. (KR) 2026-05-06 — — EP disclosed
US-12617795-B2 Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators ASTRAZENECA AB (SE) 2026-05-05 — — US disclosed
US-20250333424-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-10-30 — — US disclosed
EP-4634194-A1 SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 — — EP disclosed
EP-4634193-A1 SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 — — EP disclosed
EP-4626888-A1 COMPOUNDS Redx Pharma Limited (GB) 2025-10-08 — — EP disclosed
EP-2209775-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB Pharma, S.A. (BE) 2010-07-28 — — EP disclosed
WO-2010038060-A1 HETEROCYCLIC JAK KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-03-18 — — US disclosed
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-03-18 — — US disclosed
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-03-18 — — US disclosed
WO-2010014939-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-02-04 — — WO disclosed
WO-2010014939-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-02-04 — — WO disclosed
EP-2125757-A1 MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS Novartis AG (CH) 2009-12-02 — — EP disclosed
WO-2009047255-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2009-04-16 — — WO disclosed
WO-2008101665-A1 MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS NOVARTIS AG (CH) 2008-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146050-A1 KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES KRAS, NRAS, HRAS POLB 1128/4885PARP1 932/4885TNKS2 1442/4885
US-20250333424-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 POLB 137/4885PARP1 875/4885TNKS2 845/4885
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE MTOR, TYMS, DTYMK POLB 316/4885PARP1 2488/4885TNKS2 176/4885
US-12630552-B2 Inhibitors of KRAS G12C KRAS, NRAS, HRAS POLB 729/4885PARP1 1436/4885TNKS2 2916/4885
US-12617795-B2 Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators KCNC1, TRPC6, KCNH2 POLB 2417/4885PARP1 3361/4885TNKS2 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.